logo-eroxon logo-eroxon
CONSUMER WEBSITE
  • home
  • Erectile dysfunction
  • eroxon
  • Treating ED
  • Information
  • FAQ
  • home
  • Erectile dysfunction
  • eroxon
  • Treating ED
  • Information
  • FAQ
auteur: HCP Brochure
DOWNLOAD

HCP BROCHURE

FAQ

Frequently asked questions about Eroxon
What is the set-up of study FM57?

Eroxon formed part of this double-blind study. 250 subjects using Eroxon were studied in nine Eastern European countries over a 12-week period. Results were assessed over the 12-week period with a minimum of one intercourse attempt per week and compared with the pre-treatment or baseline ED. (Baseline levels were determined over a 4-week run in period where subjects were asked to attempt intercourse at least once per week without the use of any treatment to help their ED). A variety of other measures included onset of action and safety.

What is the set-up of study FM71?

This study was constructed with the advice of the US FDA and was run in three European countries and the United States. 96 patients used either Eroxon or tadalafil 5mg for a 24-week period. Results were assessed at 24 weeks against baseline (determined on the same basis as FM57) along with other measures including onset of action and safety.

Why are there no placebo controlled studies?

Eroxon, was the “placebo” used in FM57 and gave surprising results having efficacy approximately double that normally achieved in ED studies with regular placebos. Moreover, when assessed against internationally accepted criteria for clinical effectiveness (Rosen and Araujo) the efficacy of Eroxon exceeded the minimal clinically important differences (MCID).

Frequently asked questions about Eroxon
SHIM

Download

Product information & training tools

  • ESSM Poster by Dr David Ralph
  • HCP Brochure
logo-eroxon

Eroxon is a medical device. Always read the label

1 FM57 Clinical Investigation Report dated 6th April 2019 FM71 Clinical Investigation Report dated April 6th 2020

Links

  • home
  • Erectile dysfunction
  • eroxon
  • Treating ED
  • Information
  • FAQ
  • Terms of Use
  • Privacy Notice
  • Cookies Notice